ClinicalTrialsFinder
RecruitingPhase 1NCT07584226

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors

Sponsor

Relay Therapeutics, Inc.

Enrollment

35 participants

Start Date

Mar 9, 2026

Study Type

INTERVENTIONAL

Conditions

NRAS MutationNRAS Q61RNRAS Q61KNRAS Q61LNRAS Q61HNRAS G12DNRAS G13RNRAS G13DNRAS G12VAdvanced NRAS-Mutant MelanomaAdvanced NRAS-Mutant Solid Tumors

Summary

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called RLY-8161 for people with advanced nras-mutant melanoma, advanced nras-mutant solid tumors, and other related conditions. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRLY-8161

RLY-8161 is an NRAS-selective inhibitor

Locations(9)

University of California, Los Angeles

Los Angeles, California, United States

University of California, San Francisco

San Francisco, California, United States

University of Colorado Hospital

Aurora, Colorado, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

START Midwest, LLC

Grand Rapids, Michigan, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Sarah Cannon Research Institute Oncology Partners

Nashville, Tennessee, United States

NEXT Virginia

Fairfax, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07584226

Related Trials

Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma

NCT07750067